Amgen Q3 FY25: where the revenue came from and where it went
The whole income statement of Amgen for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 5, 2025
Revenue$9.6B
+12% year over year
Gross profit$6.5B
68% margin
Operating profit$2.5B
26% margin
Net profit$3.2B
34% margin
Net profit is larger than what operations earned, because the statement adds $1.4B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 9.6 | 100% | +12% |
| Other revenue | 3.5 | 37% | |
| Other products | 1.9 | 19% | +36% |
| Prolia | 1.1 | 12% | +9% |
| Repatha (evolocumab) | 0.8 | 8% | +40% |
| Otezla | 0.6 | 6% | +4% |
| Enbrel | 0.6 | 6% | −30% |
| Tepezza | 0.6 | 6% | +15% |
| Evenity | 0.5 | 6% | +36% |
| Cost of revenue | −3.1 | 32% | |
| Gross profit | 6.5 | 68% margin | +7pp |
| SG&A | −1.7 | 18% | −1pp |
| Other | −2.2 | 23% | +0pp |
| Operating profit | 2.5 | 26% margin | +2pp |
| Other income, net | 1.4 | ||
| Tax | −0.7 | ||
| Net profit | 3.2 | 34% margin | +0pp |
107 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest